Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07575308 · ClinicalTrials.gov registry record · Phase 2
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
A Phase 2 study, sponsored by Alnylam Pharmaceuticals.
- Not yet
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT07575308 is a Phase 2 study that has not yet begun recruiting, run by Alnylam Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT07575308, a Phase 2 study, has not yet begun recruiting, sponsored by Alnylam Pharmaceuticals.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB
Interventions
- DRUG ALN-6400
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2028-11-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07575308
The ClinicalTrials.gov registry entry for NCT07575308 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALN-6400 is the first listed.
NCT07575308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07575308 about?
NCT07575308 is a clinical study titled "HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB". The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB
What is the current status of trial NCT07575308?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2026-06-30. Estimated completion is 2028-11-29.
What interventions are being tested in trial NCT07575308?
The interventions under investigation include: ALN-6400 (DRUG).
Who is sponsoring clinical trial NCT07575308?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.